US 9,845,364 B2Granted

Anti-ADAM28 antibody for treating cancer

AssigneesGeneFrontier Corporation, Keio University

InventorsAkira Miyakoshi, Rena Matsumoto, Shizue Katoh, Yuki Hayami, Satsuki Mochizuki, Masayuki Shimoda, Yasunori Okada

Life of this patent

Estimating the term…

Abstract

The present invention provides an antibody that specifically binds to human ADAM28, inhibits enzyme activity of human ADAM28, and has an activity to suppress metastasis of a cancer cell that expresses human ADAM28. The antibody of the present invention can be a human antibody.

Claims13

Dependent claims

An antibody specifically binding to human ADAM28 at an epitope comprising the amino acid sequence shown in SEQ ID NO:

22, and having an activity to inhibit enzyme activity of human ADAM28.

Dependencies are inferred from the claim text.

Facts

Application: 14/440,391Filed 1 Oct 2013 · us provisional application
Priority: 9 Nov 2012
Published: US 2015/0274840 A11 Oct 2015
Granted: 19 Dec 2017
Term ends: Not estimatedThe source records don’t support an estimate.

Classification16 codes

C07K 16/40
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against enzymes
A61P 35/00
Antineoplastic agents
A61P 35/04
Antineoplastic agents: specific for metastasis
C07K 16/2896
Against receptors, cell surface antigens or cell surface determinants: against molecules with a "CD"-designation, not provided for elsewhere

Family

Application61/724,484Us provisional application · filed 9 Nov 2012
US 2015/0274840 A1Pre-grant publication · published 1 Oct 2015
US 9,845,364 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results